Content area

|
|

Spinal muskelatrofi behandlet med nusinersen

Forfatter(e)
Magnus Spangsberg Boesen1, 2, Simon Albrechtsen1 & Alfred Peter Born1 1) BørneUngeKlinikken, Rigshospitalet2) Børne- og Ungeafdelingen,
Herlev Hospital

Ugeskr Læger 2019;181:V09180639
Reference: 
Ugeskr Læger 2019;181:V09180639
Sidetal: 

Magnus Spangsberg Boesen, Simon Albrechtsen &
Alfred Peter Born:

Spinal muscular atrophy treated with nusinersen

Ugeskr Læger 2019;181:V09180639

Spinal muscular atrophy (SMA) is an autosomal recessive disorder, which causes degeneration of peripheral nerves and muscles. It usually presents in childhood due to an insufficient level of survival motor neuron protein. This is a case series of three children, who had SMA type 1 or 2 and were treated with nusinersen from the age of five months, 16 months, and five years, respectively. At one-year follow-up, all children had improved motor function, but the child, who was treated from the age of five months, had more pronounced motor improvements than the other children. In conclusion, nusinersen seems to improve motor development in SMA, and an early treatment start is crucial.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Anette Bygum | 19/05
10 kommentarer
af Hans-Iver G. F.-D Kley | 18/05
1 Kommentar
af Per Bonding | 17/05
1 Kommentar
af Jakob Ramlau | 15/05
1 Kommentar
af Svend Erik Heiselberg | 12/05
1 Kommentar